Evonik industries licenses ERGO genomics platform for production of specialty chemicals from microbial genomes

24 November 2008

Integrated Genomics, Inc has licensed the ERGO genomics platform for use in research and production systems to Evonik Industries, a global leader in specialty chemicals.

Under the terms of the agreement, scientists of the Evonik Science-to-Business Center Biotechnology will use the ERGO system to optimize their production strains and find new methods for high yield production of specialty chemicals.

“We have found the ERGO discovery system to be an exceptionally useful tool for our metabolic engineering projects and expect that it will assist us in developing new production strains for higher and more cost effective production of biological compounds,” said Dr Thomas Haas, Director Science-to-Business Biotechnology Center at Evonik.

Optimised for analysis of microorganisms, ERGO integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature. Reaching beyond conventional systems for functional analysis by DNA sequence alone, Integrated Genomics' platform combines pattern-based analyses with a repertoire of comparative genomics tools for gene visualisation in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods and gene fusions.

ERGO contains more than 1500 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways.

Bookmark this page

To top